Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:MNK's 10-Y Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

MNK Guru Trades in Q1 2016

Joel Greenblatt 580,887 sh (New)
David Dreman 4,027 sh (+1883.74%)
Ken Heebner 1,125,000 sh (+69.17%)
John Paulson 8,949,380 sh (+3.78%)
First Eagle Investment 187 sh (unchged)
Louis Moore Bacon Sold Out
Jeremy Grantham Sold Out
George Soros Sold Out
Paul Tudor Jones 7,622 sh (-5.87%)
Mario Gabelli 14,562 sh (-6.43%)
» More
Q2 2016

MNK Guru Trades in Q2 2016

Steven Cohen 120,400 sh (New)
David Dreman 4,448 sh (+10.45%)
First Eagle Investment 187 sh (unchged)
Mario Gabelli 14,562 sh (unchged)
John Paulson 8,371,080 sh (-6.46%)
Ken Heebner 1,014,000 sh (-9.87%)
Paul Tudor Jones 5,434 sh (-28.71%)
Joel Greenblatt 246,825 sh (-57.51%)
» More
Q3 2016

MNK Guru Trades in Q3 2016

Jim Simons 207,102 sh (New)
Paul Tudor Jones 7,336 sh (+35.00%)
Joel Greenblatt 327,572 sh (+32.71%)
First Eagle Investment 187 sh (unchged)
David Dreman 4,448 sh (unchged)
Steven Cohen Sold Out
Mario Gabelli 14,462 sh (-0.69%)
John Paulson 7,974,472 sh (-4.74%)
Ken Heebner 880,500 sh (-13.17%)
» More
Q4 2016

MNK Guru Trades in Q4 2016

Steven Cohen 120,900 sh (New)
Paul Tudor Jones 19,556 sh (+166.58%)
Mario Gabelli 17,425 sh (+20.49%)
John Paulson 7,976,872 sh (+0.03%)
First Eagle Investment 187 sh (unchged)
Joel Greenblatt Sold Out
Ken Heebner Sold Out
Jim Simons Sold Out
David Dreman 84 sh (-98.11%)
» More
» Details

Insider Trades

Latest Guru Trades with MNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Traded in other countries:MCD.Germany,
Mallinckrodt PLC along with its subsidiaries operates in a specialty biopharmaceutical and nuclear imaging business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and nuclear imaging agents.

Mallinckrodt PLC was incorporated in Ireland on January 9, 2013. The Company along with its subsidiaries operates in a specialty biopharmaceutical business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products. Its therapeutic areas of focus include autoimmune and rare disease specialty areas (including neurology, rheumatology, nephrology and pulmonology); immunotherapy and neonatal respiratory critical care therapies; pain management; and central nervous system drugs. It also supports the diagnosis of disease with nuclear medicine imaging agents. The Company operates in two segments including Specialty Brands and Specialty Generics. Specialty Brands segment produces and markets branded pharmaceuticals and biopharmaceuticals products for autoimmune and rare diseases (including in the specialty areas of neurology, rheumatology, nephrology and pulmonology); immunotherapy and neonatal respiratory critical care therapies; and central nervous system drugs. Its Specialty Brands product portfolio includes Acthar an injectable biopharmaceutical drug; Ofirmev a proprietary intravenous formulation of acetaminophen indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics and the reduction of fever; Inomax a vasodilator that, in conjunction with ventilatory support and other appropriate agents, is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension; Therakos immunotherapy provides immunotherapy treatment platforms that enhance the ability of a patient's immune system to fight disease; and Exalgo a long-acting, once-daily form of hydromorphone. Specialty Generics segment produces specialty generic pharmaceuticals and active pharmaceutical ingredients consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. The Specialty Generics product portfolio includes hydrocodone (API) and hydrocodone-containing tablets; hydrocodone (API) and hydrocodone-containing tablets; methylphenidate HCl extended-release tablets USP (CII); and other controlled substances, including acetaminophen (API) products. Its competitors include Allergan, Inc., Endo Health Solutions Inc., Johnson & Johnson, Noramco, Inc, Johnson Matthey plc, Mylan N.V., Pfizer Inc., Purdue Pharma L.P., Lantheus Medical Imaging, Inc, Teva Pharmaceutical Industries Ltd, IBA Group, and POLATOM. The development, manufacture, marketing, sale, promotion, & distribution of its products are subject to comprehensive government regulation that governs and influences the development, testing, manufacturing, processing, packaging, holding, record keeping, safety, efficacy, approval, advertising, promotion, sale, distribut


Forward P/E 7.25
MNK's Forward P/E is ranked higher than
94% of the 88 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.46 vs. MNK: 7.25 )
Ranked among companies with meaningful Forward P/E only.

Buy Back


Valuation & Return


More Statistics

Revenue (TTM) (Mil) $3,296
EPS (TTM) $ 2.50
Short Percentage of Float11.16%
52-Week Range $42.67 - 85.83
Shares Outstanding (Mil)104.69

Analyst Estimate

Sep17 Sep18 Sep19
Revenue (Mil $) 3,311 3,359 3,438
EPS ($) 7.50 8.29 9.13
EPS w/o NRI ($) 7.50 8.29 9.13
EPS Growth Rate
(3Y to 5Y Estimate)
Dividends Per Share ($)
» More Articles for MNK


Articles On GuruFocus.com
David Einhorn Converses on Range of Topics, Stocks With New York Times Editor Oct 20 2016 
10 Stocks David Dreman Is Buying Sep 21 2016 
Swiss Generics Manufacturer Has Strong 1st Half of Year Aug 22 2016 
Siegfried Holdings, Held by Tweedy Browne, Way Undervalued Jul 22 2016 
John Paulson Raises Stake in Valeant, Teva Pharmaceutical Mar 18 2016 
John Paulson Keeps Gold, Buys Drug Manufacturers Nov 17 2015 
Pioneer Investments Adds to Stakes in Hartford Financial Group, Reynolds American Nov 13 2015 
Andreas Halvorsen Buys AIG, Google, 3 More as Top New Stocks May 29 2015 
Only Buy Luxury At A Deep Discount Apr 01 2015 
Mallinckrodt Has Brighter Days Going Ahead Mar 10 2015 

More From Other Websites
MALLINCKRODT PLC Files SEC form 8-K, Change in Directors or Principal Officers Feb 23 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Feb 23 2017
MNK INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class... Feb 22 2017
Coverage initiated on Mallinckrodt plc by Canaccord Genuity Feb 22 2017
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against... Feb 20 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed a Complaint to Recover... Feb 17 2017
Blog Coverage The Biologics License Application for Mylan-Biocon's Proposed Biosimilar -... Feb 17 2017
We dug into the drug company Martin Shkreli sold out to the feds, and man is it ugly Feb 16 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Feb 16 2017
Mallinckrodt plc -- Moody's assigns Ba1 to Mallinckrodt's new senior secured term loan Feb 15 2017
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Feb 15 2017
MNK INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Mallinckrodt plc Feb 14 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Investors in... Feb 13 2017
Medicare spent $650M on 1 drug of questionable use: OHSU study Feb 13 2017
MALLINCKRODT PLC Financials Feb 11 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against... Feb 10 2017
LESS THAN TWO MONTHS REMAIN FOR MALLINCKRODT INVESTORS: Hagens Berman Reminds Mallinckrodt Investors... Feb 10 2017
MNK LOSS NOTICE: Rosen Law Firm Reminds Mallinckrodt Public Limited Company Investors of Important... Feb 08 2017
Mallinckrodt receives subpoenas Feb 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)